

Declaration of Conformity of the Management Board and the Supervisory Board of BioNTech SE with the German Corporate Governance Code (“Code”)

The Management Board and Supervisory Board have dealt in detail with the recommendations of the Corporate Governance Code (“Code”) and on April 7, 2021 adopted the following Declaration of Conformity pursuant to Section 161 (1) of the German Stock Corporation Act (*AktG*), which is issued in accordance with the Code in conjunction with the Corporate Governance Declaration pursuant to Section 315d in conjunction with Section 289f of the German Commercial Code (*HGB*):

With the exception of the points listed below, BioNTech SE has complied with all recommendations of the Code in the version from December 16, 2019 and will continue to comply with them in the future.

- Contrary to Item F.2 of the Code, the Group management report has not been made available within 90 days of the end of the financial year. However, the Company publishes and files its annual reports on Form 20-F with the US Securities and Exchange Commission within this period, which contain comparable information. In comparison to the 2019 Group management report, the Company published the 2020 Group management report shortly after the 90 day period and, therefore, reduced the time period between the end of the 90 day deadline and the publication of such report. In future, the Company intends to publish the Group management report within the above-mentioned period.
- The variable remuneration for the Management Board is only payable if the defined stringent performance criteria are met. If necessary, the Supervisory Board is authorized to reduce the remuneration pursuant to Section 87 para. 2 of the German Stock Corporation Act (*AktG*). At present, only part of the variable compensation can be withheld or reclaimed. However, the compensation system is currently being revised and will be updated in the near future with regard to further options for withholding or reclaiming compensation (see Item G.11 of the Code).
- The compensation structure of the Management Board has so far taken into account the long-term development of the Company in the form of long-term incentive compensation. Innovation as a non-financial performance indicator for the sustainable development of the Company is taken into account by setting specific corporate targets as part of the short-term incentive compensation. A link between sustainability and the long term, as well as the inclusion of further sustainability objectives such as the implementation of environmental, governance and social issues, is currently being investigated by the Compensation, Nominating and Corporate Governance Committee (cf. Principle 23 of the Code).

Mainz, April 07, 2021

BioNTech SE

Für den Vorstand

Prof. Dr. Ugur Sahin
Vorstandsvorsitzender (Chief Executive
Officer, CEO)

Dr. Sierk Poetting
Finanzvorstand (Chief Financial Officer, CFO)
und operativer Geschäftsführer
(Chief Operating Officer, COO)

Für den Aufsichtsrat

Helmut Jeggle
Aufsichtsratsvorsitzender